The initial areas of development for infirst Healthcare focused on medications to treat Common Cough and Inflammatory Pain conditions. Treatment of Chronic Wounds and everyday GI symptoms have since been added to the portfolio. Common Cough and pain as well as GI symptoms are among the most common ailments when it comes to self-medication but also the most common symptoms presented to General Practitioners (GP’s). The incidence of chronic wounds is increasing rapidly in line with the ageing of the population.
Cough affects most consumers and patients and a significant proportion of sufferers experience unproductive cough symptoms, sometimes lasting for weeks and months, long after any underlying infection has gone.
In a market defined by products with variable effectiveness, many of which have never been clinically assessed and which can cause uncomfortable side effects, including misuse and abuse (because of their narcotic /opioid nature), sufferers may be found to adjust their lifestyles, avoiding theatre and concert visits, or social gatherings, in order to cope with their symptom.
Treatments for cough, which have been assessed in either clinical trials or ‘real world’ observation studies and which are non-narcotic / non-opioid, therefore define the agenda for infirst Healthcare's cough programme.
Similarly pain and inflammation are complex and multi-facetted conditions that are not always well served or well looked after. For example, acute inflammatory joint pain, which is a feature of flare-ups of long-term musculoskeletal conditions or following trauma, is poorly served.
Each year around a fifth of the population consults their general practitioner (GP) about a painful musculoskeletal condition. This amounts to over 100,000 consultations a day. Despite some significant progress in the long-term treatment of conditions such as osteoarthritis (OA), treatments to arrest pain during acute flare-ups are limited and are known to be accompanied by risk of side effects.
As a result, The Department of Work and Pensions estimated that 36 million working days were lost because of OA in 1999-2000 in Great Britain.
infirst Healthcare aims to take well known drugs, refine them and make them more fit for purpose, more specific for the pain which comes with inflammatory surges, so that acute and flaring pain can be effectively treated.
Chronic wounds are slow – or non-healing wounds that can last for weeks, months or years despite adequate and appropriate care and which can have a significant impact on the quality of life of sufferers. Among the most common chronic wound conditions are diabetic foot ulcers, venous leg ulcers, and pressure sores, with an estimated overall prevalence of more than 6.5 million sufferers in the US alone.
Chronic wounds is a high unmet-need condition and risk increases with age. The primary risk groups are those over 80 years old with an annual incidence to develop venous ulcers of 20 per 1000, hospital in-patients with a risk to develop pressure ulcers of 40 per 1000 and diabetic patients may have a lifetime risk of developing foot ulcers as high as 25%. It is estimated to be over 7,000 amputations in people with diabetes in England alone and the majority of diabetes-related amputations are caused by a foot ulcer or infection failing to heal. The cost to the NHS directly linked to chronic wound care is estimated to be 2.3bn–3.1bn per year, with signs of significant growth as the patient population continues to age.
Lack of oxygen (hypoxia) is a core issue in impaired wound healing. Granulox is a haemoglobin spray, which addresses this challenge. Once applied it transports oxygen from the surrounding air down to the wound bed.
Everyday digestive Symptoms
Digestive health complaints can have many reasons ranging from diet to physiologic illness to functional disorders to stress and environmental causes. While complaints commonly vary in frequency and can be recurrent, most symptoms are transient in nature, yet bothersome and painful, effecting quality of life. infirst believes that treatments to relieve symptoms should be effective and fast, yet appropriate with regard to the systemic impact. 60% of the US adult population will experience some type of gastroesophageal reflux disease (GERD) within a 12 month period and 20-30% will have weekly symptoms.
Coughing has effected sleep in nine out of ten adults (89%)